Literature DB >> 15008801

Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice.

C Barbui1, A Ciuna, M Nosé, S B Patten, M Stegagno, L Burti, F Amaddeo, M Tansella.   

Abstract

OBJECTIVE: To estimate the proportion of off-label prescriptions of antipsychotics (APs) in ordinary in-patient practice.
METHOD: From the South-Verona Psychiatric Case Register all admissions to the in-patient unit during 2001-02 were extracted. Prescriptions of APs were defined off-label when dispensed outside the licensed indications. In addition, the proportion of "non-classical prescriptions" was calculated.
RESULTS: During the 2 years surveyed AP agents were prescribed in 311 cases. Nearly 50% of second-generation AP prescriptions were for an off-label indication. In contrast, <15% of first-generation AP prescriptions were for an off-label indication. About 30% of first- and second-generation agents were prescribed for a non-classical indication.
CONCLUSION: Approved labels for second-generation AP agents cover a much narrower range of indications than any of the first-generation agents, and this explains the higher proportion of off-label prescriptions. In contrast, the everyday use of first- and second-generation APs cover a similar range of clinical indications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008801     DOI: 10.1111/j.1600-0447.2003.00283.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  9 in total

1.  Drug treatment modalities in psychiatric inpatient practice: a 20-year comparison.

Authors:  Corrado Barbui; Arcangelo Ciuna; Michela Nosè; Deborah Levi; Margherita Andretta; Scott B Patten; Francesco Amaddeo; Michele Tansella
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-19       Impact factor: 5.270

Review 2.  Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research.

Authors:  Nasra Haroun; Laura Dunn; Ansar Haroun; Kristin S Cadenhead
Journal:  Schizophr Bull       Date:  2005-10-05       Impact factor: 9.306

3.  Off-label use of contrast agents.

Authors:  P Reimer; R Vosshenrich
Journal:  Eur Radiol       Date:  2008-02-15       Impact factor: 5.315

4.  Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.

Authors:  Philip Sugarman; Amy Mitchell; Catherine Frogley; Geoffrey L Dickens; Marco Picchioni
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

5.  Development of a registry for monitoring psychotropic drug prescriptions: aims, methods and implications for ordinary practice and research.

Authors:  Corrado Barbui; Michela Nosè; Gianluca Rambaldelli; Chiara Bonetto; Deborah Levi; Scott B Patten; Michele Tansella
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

6.  Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment.

Authors:  McKee J McClendon; Santiago Hernandez; Kathleen A Smyth; Alan J Lerner
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

7.  Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients.

Authors:  Daniel M Hartung; Jennifer P Wisdom; David A Pollack; Ann M Hamer; Dean G Haxby; Luke Middleton; Bentson H McFarland
Journal:  J Clin Psychiatry       Date:  2008-10       Impact factor: 4.384

8.  Off-Label Use of COVID-19 Vaccines from Ethical Issues to Medico-Legal Aspects: An Italian Perspective.

Authors:  Davide Ferorelli; Lorenzo Spagnolo; Maricla Marrone; Serena Corradi; Maria Silvestre; Federica Misceo; Francesco Paolo Bianchi; Pasquale Stefanizzi; Biagio Solarino; Alessandro Dell'Erba; Silvio Tafuri
Journal:  Vaccines (Basel)       Date:  2021-04-23

9.  Off-label Psychotropics Use: Isn't it Now an Inevitable and a "Norm" in Psychiatry?

Authors:  Sourav Khanra; Basudeb Das
Journal:  Indian J Psychol Med       Date:  2018 Jul-Aug
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.